Daré Bioscience, Inc. to Present at the 2017 BIO Investor Forum

SAN DIEGO, Oct. 10, 2017 -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will present at the 2017 BIO Investor Forum on Wednesday, October 18, 2017 at 9:15 a.m. Pacific Time in San Francisco, CA. Ms. Johnson will provide a Daré overview and business update.

In addition, Ms. Johnson will participate in a BIO Investor Forum panel entitled, “Practical Approaches for Improving Leadership Diversity,” on Tuesday, October 17, 2017 at 4:15 p.m. Pacific Time.

The company presentation will be webcast live and may be accessed by visiting Daré's website at http://ir.darebioscience.com. A replay of the webcast will be available for 10 business days.

About Daré Bioscience

Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. Daré is driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women. The Company is initially focused on the areas of contraception, vaginal health and fertility. Daré’s first product candidate, Ovaprene™, is a monthly non-hormonal contraceptive ring that is currently in clinical studies. Daré's executive management team brings experience in global women's healthcare as well as a track record of success in prior ventures in financing, partnering, commercializing, and achieving regulatory approval for medical devices, therapeutics and diagnostics. For more information on Daré, please visit www.darebioscience.com.  

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995 regarding matters that are not historical facts, including statements relating to Daré's expectations regarding the anticipated market demands for its products, the safety and effectiveness of its products, market acceptance of Daré’s products and the qualifications and expertise of Daré’s management team. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the initiation and completion of clinical trials; availability and timing of data from ongoing and future clinical trials and the results of such trials; whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals; claims of infringement and other risks relating to Daré's owned and licensed intellectual property rights, and other factors discussed in the "Risk Factors" section of Daré's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2017. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in Daré’s reports to the Securities and Exchange Commission, including Daré’s reports on Forms 10-Q, 8-K and 10-K. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. Daré specifically disclaims any obligation to update any forward-looking statements included in this press release.

CONTACT:

[email protected]

Phone: 858-926-7655

Source: Daré Bioscience